Is Meloxicam Good for Gout? Benefits and Limits

Meloxicam works for acute gout flares, reducing pain, swelling, and inflammation at a level comparable to other anti-inflammatory drugs in its class. It is not, however, the first NSAID most rheumatologists reach for during a gout attack, largely because it takes longer to start working than faster-acting alternatives. That gap between “effective” and “ideal” is where the real story lies, and it matters if you or your doctor are weighing meloxicam against other options.

How Meloxicam Fits Into Gout Treatment

Gout flares happen when urate crystals in a joint trigger an intense inflammatory response. The standard approach is to shut down that inflammation as quickly as possible. Three drug classes have strong evidence behind them for this job: NSAIDs, colchicine, and corticosteroids.¹ Meloxicam belongs to the NSAID group, but it sits in a somewhat unusual spot within that family. It preferentially blocks the COX-2 enzyme, which drives inflammation, while partially sparing COX-1, the enzyme that helps protect your stomach lining. That makes it “COX-2 preferential” rather than fully selective like celecoxib or etoricoxib. In practice, this means meloxicam tries to split the difference between strong anti-inflammatory action and a gentler profile on the gut.

What the Clinical Evidence Actually Shows

A head-to-head trial comparing meloxicam (15 mg daily) with rofecoxib and diclofenac in acute gout found that all three drugs produced significant improvements in inflammation scores by day three and day eight of treatment.² A systematic review and meta-analysis that pooled data from trials of COX-2 inhibitors against traditional NSAIDs for acute gout concluded that meloxicam has the same efficacy as non-selective NSAIDs like indomethacin and diclofenac.³ A broader Cochrane review looking across multiple trials confirmed that non-selective NSAIDs and COX-2 selective drugs produce little to no difference in pain relief, swelling reduction, or treatment success for gout flares.⁴

So meloxicam clears the bar. It reduces gout pain and swelling effectively. The question is whether it does so as quickly or conveniently as other choices, and whether its safety trade-offs make it a better or worse fit for you specifically.

The Onset Problem

Speed matters a lot during a gout attack. You want relief in hours, not days. This is where meloxicam falls behind some competitors. A trial comparing etoricoxib (120 mg) to meloxicam (15 mg) in older adults with acute gout found that etoricoxib began relieving pain in about four hours on average, while meloxicam took roughly twelve hours.⁵ At four hours after the first dose, the etoricoxib group had meaningfully greater pain improvement. By about a week in, both groups had caught up and were essentially equal in pain reduction.

A meta-analysis found a similar pattern: etoricoxib showed slightly more favorable pain scores compared to meloxicam on a Likert scale, though on a visual analog scale the two were comparable.⁶ The practical takeaway is that meloxicam can leave you waiting longer for meaningful relief during the most painful window of a gout attack. Traditional NSAIDs like indomethacin and naproxen, taken at full anti-inflammatory doses, tend to kick in faster as well, which is why many gout guidelines favor them for acute flares.

That said, meloxicam’s slower onset becomes less of an issue if the drug is being used not to extinguish a full-blown flare but to manage low-grade residual inflammation or for anti-inflammatory prophylaxis during the early months of urate-lowering therapy, when minor flares are common.⁷

Stomach and Gut Safety

One of the reasons doctors sometimes choose meloxicam over older NSAIDs like indomethacin or diclofenac is the hope of fewer gastrointestinal problems. Meloxicam’s partial COX-2 selectivity does provide some GI advantage over fully non-selective NSAIDs, but the protection is not absolute. A large observational study of over 19,000 patients taking meloxicam in general practice found a dyspepsia rate of about 28 per 1,000 patient-months in the first month of use, along with 33 reports of upper GI bleeding across the study period, a rate of roughly 0.4 per 1,000 patient-months.⁸ That same study found that having any GI problems in the past year tripled the rate of dyspepsia and quadrupled the rate of peptic ulcers while on meloxicam.

A pharmacology review noted that while meloxicam compares favorably to traditional non-selective NSAIDs on GI risk, it appears to carry greater GI risk than highly selective COX-2 drugs like celecoxib.⁹ In the meta-analysis that pooled COX-2 inhibitors against non-selective NSAIDs for gout, the overall adverse event rate was about 8% lower in the COX-2 group, though that difference was not statistically significant.³

So meloxicam is gentler on the stomach than indomethacin, which is notoriously hard on the gut, but it is not risk-free. If you have a history of ulcers, GI bleeding, or even frequent heartburn, your doctor should factor that in when deciding whether meloxicam is worth using for gout or whether a corticosteroid or colchicine would be safer.

Cardiovascular Risk

This is where meloxicam’s profile gets more complicated. All NSAIDs carry some degree of cardiovascular risk, but the size of that risk varies. A large population-based study found that current meloxicam use was associated with an adjusted odds ratio of about 1.38 for heart attack compared to people who had used NSAIDs only in the remote past. That figure was similar to diclofenac (around 1.37), while naproxen showed a lower and statistically non-significant increase (about 1.12).¹⁰

A systematic review of meloxicam’s cardiovascular, vascular, and renal risks found a modest overall increase in composite cardiovascular risk, driven primarily by vascular events rather than heart attacks specifically. The composite risk was modestly elevated, but when the data were broken down, the heart attack risk alone was not statistically significant, and there was no increase in renal risk.¹¹ A separate large systematic review of observational data recommended that meloxicam be avoided in patients at high cardiovascular risk, placing its risk profile in the same ballpark as ibuprofen and celecoxib, and noting it should probably not be used as a first-line choice for anyone with established heart disease.¹²

This matters for gout patients specifically because gout itself is associated with higher rates of cardiovascular disease. People with gout are more likely to have hypertension, metabolic syndrome, and coronary artery disease. So the population most likely to need acute gout treatment is also the population most vulnerable to the cardiovascular downside of NSAIDs, including meloxicam.

Kidney Concerns and Why They Matter for Gout

Kidney function occupies a central place in gout management. Your kidneys are responsible for clearing uric acid, and impaired kidney function is both a cause and a consequence of long-standing gout. NSAIDs as a class can reduce blood flow to the kidneys and potentially worsen existing kidney disease, which creates a genuine tension when treating gout flares.

A review of gout treatments in people with kidney impairment noted that while NSAIDs are effective for flares, their potential to harm kidney function is well documented. The risk of NSAID-induced acute kidney injury rises as baseline kidney function declines. A systematic review of observational studies found that overall NSAID use did not accelerate chronic kidney disease progression, but high-dose use did.¹³ That distinction between regular doses and high doses is relevant because gout flares often tempt people to take more than the standard amount to get faster relief.

If you already have reduced kidney function, most guidelines suggest treating acute gout flares with corticosteroids or colchicine at adjusted doses rather than any NSAID, meloxicam included. If your kidney function is normal, short courses of meloxicam for a gout flare are generally considered safe, but longer use or repeated courses deserve a conversation with your doctor about monitoring.

Meloxicam in Older Adults

Gout becomes more common with age, and many people dealing with recurrent flares are over sixty. This is exactly the population where meloxicam’s risks stack up most unfavorably. A review of gout management in older adults highlighted that NSAID use in this group is limited by the higher prevalence of peptic ulceration, ischemic heart disease, hypertension, and renal impairment.¹⁴ Older adults are more likely to be on blood thinners, antihypertensives, or other medications that interact with NSAIDs, and they are more likely to have the GI, cardiovascular, and kidney vulnerabilities that make any NSAID riskier.

That said, meloxicam’s once-daily dosing and relatively lower GI irritation compared to indomethacin make it one of the better-tolerated NSAIDs if an NSAID must be used in an older patient. The trial that compared etoricoxib to meloxicam specifically enrolled older adults (average age around 64), and both drugs were tolerated reasonably well over seven days of treatment.⁵ The issue is not that meloxicam is uniquely dangerous for older people, but that the entire NSAID class becomes harder to justify as competing health problems accumulate.

Where Meloxicam Makes the Most Sense

Meloxicam occupies a practical niche in gout management for people who tolerate it well and do not have major cardiovascular or kidney problems. Its once-daily dosing is convenient, and its milder GI profile gives it an edge over indomethacin, which is highly effective for gout but notorious for causing stomach pain, nausea, and headaches. Meloxicam is a reasonable choice when you need an anti-inflammatory option and your doctor wants to avoid indomethacin’s side effects or when colchicine is not tolerated or contraindicated.

It also has a role during the initiation of urate-lowering therapy. When patients start allopurinol or febuxostat, mild flares are common in the first several months as urate levels shift. Some doctors prescribe a low-dose NSAID or colchicine during this period to prevent or dampen those flares. Meloxicam has been used in this prophylactic capacity, where its slower onset is less of a drawback because the goal is steady background anti-inflammatory coverage rather than rapid rescue of an acute attack.¹⁵

How Meloxicam Stacks Up Against Etoricoxib and Celecoxib

If you are looking at the COX-2 preferential and selective drugs as a group, there are meaningful differences between them for gout. Etoricoxib, where it is available (it is approved in many countries but not the United States), has the most gout-specific evidence and appears to offer faster pain relief than meloxicam in the first hours of a flare. By the end of a week, the two drugs converge in effectiveness.⁶ Celecoxib is another option, but the evidence for celecoxib in acute gout is thinner than for either etoricoxib or meloxicam, and the meta-analysis data suggest etoricoxib outperforms celecoxib on pain scores as well.

In countries where etoricoxib is not available, the practical choice often comes down to meloxicam versus indomethacin or naproxen. Indomethacin is the traditional workhorse for acute gout but has a heavy side-effect burden. Naproxen is widely available over the counter and has a somewhat more favorable cardiovascular profile than meloxicam. Meloxicam’s advantage over both is that it requires only one pill a day and is easier on the stomach for most people. Its disadvantage is the slower onset and the cardiovascular signal that puts it in a less reassuring category than naproxen for patients with heart risks.

Common Misconceptions About Meloxicam and Gout

One persistent misunderstanding is that meloxicam can lower uric acid levels or prevent future gout attacks on its own. It does neither. Meloxicam is purely an anti-inflammatory; it does not change the underlying metabolic problem that causes urate crystal deposition. Long-term gout management requires urate-lowering therapy like allopurinol or febuxostat, along with dietary and lifestyle adjustments. Meloxicam can help manage pain during flares or during the transition onto those drugs, but it is not a substitute for them.

Another misconception is that because meloxicam is available by prescription and sounds more targeted than over-the-counter NSAIDs, it must be stronger or more effective for gout. The evidence does not support that. Indomethacin, naproxen, and diclofenac at appropriate doses all perform comparably or even better in the acute setting.⁴ Meloxicam’s prescription status reflects its dosing profile and safety monitoring requirements, not superior efficacy.

Finally, some people assume that because meloxicam is “easier on the stomach,” it is safe for anyone. The large observational study of nearly 20,000 patients makes clear that GI events still occur, and prior GI history dramatically raises the odds.⁸ “Easier on the stomach” is a relative claim, not an absolute one, and it should not be confused with “safe for all stomachs.”

1
PubMed. Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline
2
Clinical Therapeutics. A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis
3
Journal of Pharmacology and Pharmacotherapeutics. A Systematic Review and Meta-analysis of Selective Cyclooxygenase-2 Inhibitors and Non-selective Non-steroidal Anti-inflammatory Drugs for Acute Gout
4
Cochrane Library. Non-steroidal anti-inflammatory drugs for acute gout
5
Chinese Journal of Geriatrics. Evaluation of efficacy and safety of etoricoxib and meloxicam in the treatment of patients with acute gout
6
BMJ Open. Comparative efficacy of traditional non-selective NSAIDs and selective cyclo-oxygenase-2 inhibitors in patients with acute gout: a systematic review and meta-analysis
7
Journal of Clinical Rheumatology. Does Starting Allopurinol Prolong Acute Treated Gout? A Randomized Clinical Trial
8
PubMed Central. The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19 087 patients in general practice in England: cohort study
9
PubMed. Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety
10
PubMed Central. Meloxicam and Risk of Myocardial Infarction: A Population-based Nested Case-control Study
11
PubMed. The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review
12
PLoS Medicine. Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies
13
Exploration of Musculoskeletal Diseases. Safety and efficacy of gout treatments in people with renal impairment
14
Journal of Pharmacy Practice and Research. Management of gout in older people
15
Dove Medical Press. Contentious Issues in Gout Management: The Story so Far